{"product_id":"lilly-ansoff-matrix","title":"Eli Lilly Ansoff Matrix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUnlock the Full Amsoff Matrix for Deeper Strategic Insight\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Eli Lilly Amsoff Matrix Analysis gives a clear view of Eli Lilly’s growth options across market penetration, market development, product development, and diversification. The page already shows a real preview of the actual analysis, so you can review the format and content before buying. Purchase the full version to get the complete ready-to-use report instantly.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eM\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003earket Penetration\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEli Lilly and Company’s tirzepatide share push\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEli Lilly and Company used Mounjaro and Zepbound to win share in type 2 diabetes and obesity. Mounjaro generated about $11.5 billion in 2024 sales, and Zepbound added about $4.9 billion, giving Eli Lilly and Company two blockbuster brands in the same incretin class. That scale makes share defense tougher for rivals, because Eli Lilly and Company can push on both demand and access at once.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSelf-pay pricing widened access fast\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEli Lilly and Company widened Zepbound access with a direct self-pay route at about $399 to $499 a month, depending on dose and package. In 2025, that lower-friction price point helped reach patients facing coverage gaps, since obesity drug uptake is still limited by payer rules and prior auth. The move converted demand into fills faster than rebate-heavy access models.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVerzenio defended oncology share at scale\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIn 2025, Verzenio remained Eli Lilly and Company’s breast cancer anchor, after 2024 sales of about $5.3 billion. Its use in both metastatic and adjuvant settings spans two major treatment stages, which keeps prescriber habits sticky and repeat use high. That broad clinical reach helped Eli Lilly and Company defend share at scale in an established oncology market.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLillyDirect reduced prescription friction\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLillyDirect cut steps between patient interest and first fill for Eli Lilly and Company, which matters in obesity and diabetes where prior authorizations and specialist wait times slow starts. In 2025, Eli Lilly and Company reported about $59.4 billion in revenue, and faster access can help convert that demand into scripts sooner.\u003c\/p\u003e\n\u003cp\u003eIn a category won by convenience and persistence, even small drops in friction can shift share. LillyDirect gives Eli Lilly and Company a tighter path from search to start, which can lift adoption for high-demand drugs like Zepbound and Mounjaro.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing scale protected demand capture\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEli Lilly and Company used its 2024 revenue base of about $45.0 billion to keep lifting manufacturing output, which made supply capture part of market penetration, not just a plant issue. In incretins, reliable supply helps convert demand into actual share, especially while rivals are still building capacity. That scale lets Eli Lilly and Company keep investing in volume, fill rates, and launches at the same time.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLilly’s 2025 growth engine: Mounjaro, Zepbound, and Verzenio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEli Lilly and Company pushed market penetration in 2025 by pairing Mounjaro, Zepbound, Verzenio, and LillyDirect with tighter access and faster starts. Revenue reached about $59.4 billion, with diabetes and obesity demand still driving share gains while supply expansion helped turn interest into fills.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003e2025 metric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003e$59.4B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMounjaro 2024 sales\u003c\/td\u003e\n\u003ctd\u003e$11.5B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eZepbound 2024 sales\u003c\/td\u003e\n\u003ctd\u003e$4.9B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVerzenio 2024 sales\u003c\/td\u003e\n\u003ctd\u003e$5.3B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\nAnalyzes Eli Lilly’s growth strategy through the four core directions of the Amsoff Matrix\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\nHelps Eli Lilly quickly relieve strategy bottlenecks with a clear Ansoff snapshot of growth options.\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eM\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003earket Development\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal rollout of Mounjaro expanded geography\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIn 2025, Eli Lilly and Company kept rolling out Mounjaro beyond the U.S., pushing it into more diabetes markets and local payer systems. That matters because Mounjaro is one of Eli Lilly and Company's two main growth brands, so each new country adds a new formulary, reimbursement path, and doctor network. Market development here is just the U.S. launch playbook repeated country by country, with local access rules shaping speed and sales.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eZepbound opened obesity demand outside the U.S.\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEli Lilly and Company used Zepbound, alongside Mounjaro, to build a 2-product incretin platform for obesity launches outside the U.S. That fits a market development move because obesity affects over 1 billion people worldwide, while treatment use is still low in many developed markets. In Q1 2025, Eli Lilly and Company reported $12.73 billion in revenue, with Zepbound sales of $2.31 billion, showing how fast demand can scale.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eKisunla created a new Alzheimer’s market entry\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEli Lilly and Company used Kisunla to enter the Alzheimer’s disease market after the U.S. FDA approved it in 2024. In 2025, Alzheimer’s affected about 7.2 million Americans age 65 and older, so this opened a large new specialist channel with amyloid PET or CSF testing, infusion-site logistics, and MRI monitoring. The market has different reimbursement and patient-selection rules than diabetes or oncology, even though it still depends on specialty care.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegional access plans broadened ex-U.S. reach\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eEli Lilly and Company is widening access in Europe, Asia-Pacific, and Latin America, so market development now means three separate regional plays, not one global rollout. Each market needs local pricing, tender bids, and supply coordination, because payers and regulators approve drugs country by country. That matters in pharma: a launch can stall if reimbursement talks or hospital tenders lag in even one major market.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialty channels extended into new care settings\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eEli Lilly and Company is pairing launches with specialty pharmacy and digital support to reach patients beyond major academic centers. In 2025, this matters in obesity, diabetes, and neurology, where care is often split across primary care, telehealth, and local specialists, so access depends on distribution, not just demand.\u003c\/p\u003e\n\u003cp\u003eThat is market development in practice: a new geography is also a new access model. By broadening specialty channels, Eli Lilly and Company can move into fragmented care settings faster and keep patients on therapy longer.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLilly’s Global Expansion Is Powering 2025 Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEli Lilly and Company’s market development in 2025 is about pushing Mounjaro, Zepbound, and Kisunla into new countries and payer systems, where access rules decide speed. This is working: Q1 2025 revenue was $12.73 billion, with Zepbound at $2.31 billion. In pharma, each new market means new reimbursement, tenders, and specialty-channel setup.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2025\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ1 revenue\u003c\/td\u003e\n\u003ctd\u003e$12.73B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eZepbound sales\u003c\/td\u003e\n\u003ctd\u003e$2.31B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eObesity prevalence\u003c\/td\u003e\n\u003ctd\u003e1B+ people\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eEli Lilly Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThis Eli Lilly Amsoff Matrix Analysis preview is the same document you’ll receive after purchase—no sample, no placeholders, just the real file. The full report includes the complete analysis in a clear, professional format. Buy now to unlock the exact version shown here.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eroduct Development\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOrforglipron is the next oral incretin bet\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEli Lilly and Company is advancing orforglipron, a once-daily oral GLP-1 in late-stage development, as a clear product-development play. A pill could remove the injection barrier for millions, while keeping the same high-demand obesity and diabetes franchise. Lilly said it expects 2025 phase 3 data across obesity, diabetes, and sleep apnea, extending a business that generated $45.0 billion in 2024 revenue.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRetatrutide targets a wider metabolic profile\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEli Lilly and Company is advancing retatrutide as a next-gen obesity and cardiometabolic therapy that hits GLP-1, GIP, and glucagon receptors. In phase 2, the top dose cut body weight by 24.2% at 48 weeks, pointing to broader metabolic control than 1-target drugs.\u003c\/p\u003e\n\u003cp\u003eThat gives Eli Lilly and Company a strong follow-on path after tirzepatide, which posted $16.5B in 2024 sales and drove $45.0B total revenue.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eKisunla evidence is moving earlier in disease\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEli Lilly and Company is pushing Kisunla beyond late-stage Alzheimer’s care into earlier disease evidence, which is the core product development move here. In the U.S., more than 7 million people live with Alzheimer’s, and many are diagnosed after major decline, so earlier use could lift the addressable market fast. As a 2025 growth signal, this shift is about turning Kisunla from a launch product into a broader clinical platform.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOmvoh is building a 2-indication GI franchise\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOmvoh is a classic product-development move: Eli Lilly and Company is extending one approved GI asset from ulcerative colitis into Crohn’s disease, so the brand now spans 2 inflammatory bowel disease indications. That broadens the addressable market without building a new molecule from scratch. In 2025, the key value is life-cycle extension, higher use per patient, and more room for long-run revenue growth.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNew delivery formats support persistence\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEli Lilly and Company is widening Zepbound access with self-pay vial formats at 2.5 mg and 5 mg, plus dose access improvements that lower the cash barrier at launch. In obesity care, where weekly injectables keep growing fast in 2025, easier packaging can cut pharmacy drop-off and support longer use. That makes delivery design part of the product, not an afterthought, because persistence supports both outcomes and repeat revenue.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEli Lilly’s Next-Gen Obesity Pipeline Targets Bigger Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEli Lilly and Company is using product development to extend its obesity and metabolic franchise, led by orforglipron and retatrutide. Orforglipron is in late-stage trials, while retatrutide showed 24.2% weight loss at 48 weeks in phase 2. That sits on top of $45.0 billion 2024 revenue and $16.5 billion Zepbound sales.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003e2025 signal\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eorforglipron\u003c\/td\u003e\n\u003ctd\u003eLate-stage oral GLP-1\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eretatrutide\u003c\/td\u003e\n\u003ctd\u003e24.2% weight loss\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eZepbound\u003c\/td\u003e\n\u003ctd\u003e$16.5B sales\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eD\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eiversification\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePOINT Biopharma added radiopharmaceutical exposure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEli Lilly and Company bought POINT Biopharma for about $1.4 billion, a clear diversification move into radiopharmaceutical cancer therapy. The deal adds a new technology platform and a different oncology submarket, including PSMA-targeted and other radioligand programs, so Eli Lilly and Company is less tied to small molecules and antibodies alone. In Amsoff Matrix terms, this is diversification into a higher-risk, higher-optionality growth path.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMorphic expanded immunology beyond Lilly core assets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLilly and Company agreed to buy Morphic for about $3.2 billion, adding oral integrin inhibitor assets. This widened Lilly and Company’s reach in inflammatory disease with a different drug modality. It is diversification because the market, mechanism, and go-to-market playbook differ from Lilly and Company’s 2025 incretin-led growth.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eKisunla diversified the portfolio into neuroscience\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEli Lilly and Company moved beyond diabetes with Kisunla, a 2024 Alzheimer’s launch that slowed cognitive decline by 35% at 76 weeks in the TRAILBLAZER-ALZ 2 study. Neuroscience has tougher trial design, ARIA safety monitoring, and more complex payer review than metabolic care. That broadens Eli Lilly and Company across 2 big growth pools, not just one, and reduces reliance on diabetes alone.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePortfolio breadth now spans 5 therapeutic areas\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eEli Lilly and Company now spans diabetes, obesity, oncology, immunology, neuroscience, and cardiovascular health. In 2025, that broader mix helped offset reliance on any one block, with Mounjaro and Zepbound still driving outsized growth while other programs added depth.\u003c\/p\u003e\n\u003cp\u003eThis 5-plus area spread lowers single-franchise risk, so a slowdown in one area does not automatically hit the whole model. It also gives Eli Lilly and Company more shots at sustained sales growth as new launches scale.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdjacent science reduces single-platform risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eEli Lilly and Company is spreading risk across GLP-1s, antibodies, oral small molecules, and radiopharmaceuticals, so one setback does not define the whole pipeline. That mix was broader in 2025 than 3 to 5 years ago, when the story leaned much more on a few drug classes. The benefit showed up in scale too, with 2025 revenue expected to stay above $50 billion as multiple platforms now feed growth.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEli Lilly’s 2025 diversification push broadens growth beyond incretins\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDiversification is a key Eli Lilly and Company Ansoff move in 2025, with POINT Biopharma adding radioligand oncology and Morphic adding oral integrin therapy. These bets expand Eli Lilly and Company beyond incretins into new drug classes, markets, and payers, so growth is less tied to one franchise. With 2025 revenue above $50 billion, the wider mix now supports scale and lowers single-product risk.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMove\u003c\/th\u003e\n\u003cth\u003e2025 role\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePOINT Biopharma\u003c\/td\u003e\n\u003ctd\u003eOncology diversification\u003c\/td\u003e\n\u003ctd\u003e$1.4B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMorphic\u003c\/td\u003e\n\u003ctd\u003eImmunology diversification\u003c\/td\u003e\n\u003ctd\u003e$3.2B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEli Lilly and Company\u003c\/td\u003e\n\u003ctd\u003e2025 revenue\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;$50B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"Balanced Scorecard","offers":[{"title":"Default Title","offer_id":53649728045398,"sku":"lilly-ansoff-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1027\/3715\/0294\/files\/lilly-ansoff-analysis.webp?v=1778890362","url":"https:\/\/balancedscorecardexamples.com\/products\/lilly-ansoff-matrix","provider":"Balanced Scorecard","version":"1.0","type":"link"}